	OF HEALTH AND HUMAN SERV	ACES	14	
10 Waterview Blvd, Parsippany NJ 07054 973-331-4900	31	DATE(S) OF INSPECTION 06/19/17, 06/21/17, 08/15/17, 08/23/17,		
Industry Information: www.fda.gov/oc/industry		3013505558		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED				
TO: Mr. Hank Incognito, R.Ph., Owner				
FIRM NAME	STREET ADDRESS			
Ideal Specialty Apothecary Inc., dba Ideal Pharmacy	2333 Morris Ave,	2333 Morris Ave, Suite B101		
CITY, STATE AND ZIP CODE	TYPE OF ESTABLISHME	TYPE OF ESTABLISHMENT INSPECTED		
Union, NJ 07083-5714	Producer of Sterile	Producer of Sterile and Non-Sterile Drug Products		
THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRE OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETER! OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE N DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:	MINATION REGARDING YOUR CON CORRECTIVE ACTION IN RESP THE INSPECTION OR SUBMIT TO	MPLIANCE. IF YOU HAVE AN O ONSE TO AN OBSERVATION,	BJECTION REGARDING AN YOU MAY DISCUSS THE	
OBSERVATION 1				
(7) (4)	) (4)	", for aseptic fill	ing or repackaging	
of sterile drug products has a negative pressure gra				
(observed at -0.117" WC on 06/19/17, -0.034" WC on 08/23/17, and qualified in "Negative Mode" on 04/28/17				
and 07/11/17). There is no assurance that lower-quality air does not contaminate the environment when the(b) (4):				
(b) (4) must be opened for cleaning, or when	(b) (4	.)	. The	
(b) (4) is also not tested for leaks each time the	(b)	(4)	l. For production	
of Medroxyprogesterone Acetate 150mg/ml Intramuscular Injection Suspension ("MPA"), the (b) (4) sterilized				
(b) (4) is aseptically filled into (b) (4) vials inside the ISO-5 (b) (4). There is no assurance that				
sterile drug product does not become contaminated by lower quality air from the unclassified room due to the				
negative pressure gradient.				
For example, approx. (b) (4) vials of "MPA" were produced and aseptically filled in the (b) (4) as part of Batch (b) (4) on 04/27/17 (Beyond Use Date: 04/2018); and approx. (b) (4) vials of "MPA", Batch (b) (4) were produced and aseptically filled on 05/02/17 (BUD 05/2018). The most recent performance of Environmental Viable Particulate Test on 04/28/17 isolated low levels of Bacillus, Micrococcus, "Staphylococcus Coagulase (-)", "Other Fungi", and Basidiomycetes fungi in the unclassified room (active air samples: total 7 CFU/1000 liters on (b) (4) plate; and total 3 CFU/1000 liters on (b) (4) plate), and "Staphylococcus Coagulase (-)", Basidiomycetes fungi, and Cladosporium fungi in the (b) (4) for (b) (4) (active air samples: total 1 CFU/1000 liters on (b) (4) plate; and total 4 CFU/1000 liters on (b) (4) plate).				
OBSERVATION 2				
Non-sterile cleaning pads are used for initial cleaning of surfaces inside the ISO-5 (b) (4), and we observed				
these stored in an open package, on a shelf in the unclassified room on 06/19/17. Additionally, a resealable pouch				
of pre-wetted sterile wipes is used for final cleaning. There is no assurance that the sterile wipes remain	g; but the pouch may be	used for more than o	ne operation.	
EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND T	TLE (Print or Type)	DATE ISSUED	
SEE STATE	Nicholas Violand, Investi	gator	50	
REVERSE COMPANY PAGE Sollowin Flam	Emmanuel J. Ramos, Inv. Zakaria Ganiyu, Investiga	ntor	08/31/2017	

	ALTH AND HUMAN SERVICES RUG ADMINISTRATION		×.				
DISTRICT OFFICE ADDRESS AND PHONE NUMBER  10 Waterview Blvd, Parsippany NJ 07054 973-331-4900  Industry Information: www.fda.gov/oc/industry		DATE(S) OF INSPECTION 06/19/17, 06/21/17, 08/02/17, 08/09/17, 08/15/17, 08/23/17, 08/31/17 FEI NUMBER 3013505558					
				NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED			
				TO: Mr. Hank Incognito, R.Ph., Owner			
FIRM NAME	STREET ADDRESS						
Ideal Specialty Apothecary Inc., dba Ideal Pharmacy	2333 Morris Ave, Suite B101						
CITY, STATE AND ZIP CODE	TYPE OF ESTABLISHMENT INSPECTED						
Union, NJ 07083-5714	Producer of Sterile and Non-Sterile Drug Products						
opening has not been established. A resealable pouch 06/19/17, but there was no production occurring at the		And the second section of the section of t					
OBSERVATION 3 There is no assurance that the ISO-5 (b) (4) is certifications (performed (b) (4). The component (b) (4) to simulate manipulations is only described dure tests. Microbiological testing (b) (4) under dynamic conditions, during any routine operation performed following HVAC construction in the productions.	ertification was done by ring particle counts, but ) of the environment ons, and was not done as	a contract compan not during airflow does not appear to	y, and the use of smoke pattern be performed				
OBSERVATION 4 Media fill studies are performed, but are not designed fill, which uses (b) (4) approx (b) (4) but a routine batch may be as many as and (b) (4) are not used during the media fill, but may process for Medroxyprogesterone Acetate Injection State as a septic filling into (b) (4), whereas the media fill in	approx. (b) (4) Eq	. The medicular transfer of the state of the	a fill lot size is repeater pump he routine (4) followed by				
OBSERVATION 5 Air handling design for the unclassified production ro HEPA filters supplying air to the room are located adj There is no assurance that air throughout the unclassif	acent to the returns, all o	nadequate on 06/19 of which are located					
OBSERVATION 6 On 06/19/17, we observed condensation forming on to which was dripping on the cart containing the (b) (4) observed to have a small yellow mark on the filter factors.	. Additionally, one o	f the HEPA filters	in the ceiling was				
SEE REVERSE OF THIS PAGE SALORING SIGNATURE SUMMER SALORING SALORI	EMPLOYEE(S) NAME AND TITLE Nicholas Violand, Investigato Emmanuel J. Ramos, Investig Zakaria Ganiyu, Investigator Neda Hamandi, Consumer Sa	r ator	08/31/2017				